Fluid Resuscitation Solutions for Burns

N/A

Waitlist Available

Led By Jean-François Cailhier, MD

Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pre-infusion to day 10 post-infusion

Awards & highlights

Study Summary

This trial is testing whether two types of fluids used to treat severe burns result in different levels of inflammation.

Who is the study for?

This trial is for severely burned patients with more than 20% of their body area affected, who can have their first blood sample taken within the first 24 hours after being burned. They must be admitted to CHUM. People cannot join if they are pregnant, had recent radiotherapy or chemotherapy, suffer from severe infections or major organ dysfunctions, Hepatitis C, HIV, cancer, immunosuppression or autoimmune diseases.Check my eligibility

What is being tested?

The study is testing two types of fluids used in early treatment: PlasmaLyte and Ringer's Lactate. It aims to see how these fluids affect inflammation in patients with severe burns by observing changes in immune response and determining which fluid better prevents complications like macrophage hyperactivation.See study design

What are the potential side effects?

While specific side effects aren't listed for this trial since it focuses on inflammatory responses rather than drug reactions, generally fluid resuscitation may cause issues such as electrolyte imbalances or allergic reactions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pre-infusion to day 10 post-infusion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pre-infusion to day 10 post-infusion

This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-infusion to day 10 post-infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in monocyte phenotype from admission to day 10

Trial Design

2Treatment groups

Experimental Treatment

Group I: Ringer's LactateExperimental Treatment1 Intervention

Seven (7) severely burned patients will be infused with Ringer's Lactate (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.

Group II: PlasmaLyteExperimental Treatment1 Intervention

Seven (7) severely burned patients will be infused with PlasmaLyte (following randomization) during the resuscitation period following admission to the ICU. 50mL of blood will be withdrawn before the first infusion and for the following days (Day 1-2-5 and 10) in order to isolate neutrophils and monocytes. Plasma will be preserved for future cytokines characterization.

Do I qualify?Apply below to find out